1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsNJSave Programs is sponsored by New Jersey Division of Aging Services. An online application that helps low-income seniors and individuals with disabilities save money on Medicare premiums, prescription costs, and other living expenses by enrolling them in various assistance programs.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: New Jersey residents aged 65 and older, or between 18 and 64 receiving Social Security Disability benefits, with annual income between $54,943 and $64,943 if single, or between $60,690 and $70,690 if married. Confirm the full requirements in the official notice before applying.
NJSave Programs is funded by New Jersey Division of Aging Services. Verify program details on the funder's official page before applying.
This opportunity targets applicants in New Jersey. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
NJDOL's FY2027 cycle runs UPSKILL, PACE, NJBUILD WMIC and GAINS with mandatory Letters of Intent in October. The $7M UPSKILL Round 1 LOI gate shut on September 23 — and the application deadline is still open.
Read articleSeven research teams will run the first clinical trials aimed at extending human healthspan under ARPA-H PROSPR contracts worth up to $144M. The milestone-based contract model breaks every convention of federal biomedical funding.
Read articleARPA-H PROSPR program funds seven research teams up to $144M to develop the first clinical trials targeting biological aging itself, testing rapamycin analogs, semaglutide, and retrotransposon inhibitors.
Read article